We are live on
!
Find out more
iShares Biotechnology ETF
317 hedge funds and large institutions have $5.3B invested in iShares Biotechnology ETF in 2014 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 96 increasing their positions, 117 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
39% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 31
21% more funds holding in top 10
Funds holding in top 10: 14 → 17 (+3)
20% more capital invested
Capital invested by funds: $4.42B → $5.3B (+$882M)
4% more funds holding
Funds holding: 306 → 317 (+11)
18% less repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 117
22% less call options, than puts
Call options by funds: $461M | Put options by funds: $594M
Holders
317
Holders Change
+11
Holders Change %
+3.59%
% of All Funds
9.2%
Holding in Top 10
17
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+21.43%
% of All Funds
0.49%
New
43
Increased
96
Reduced
117
Closed
31
Calls
$461M
Puts
$594M
Net Calls
-$134M
Net Calls Change
+$103M
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$280M |
| 2 |
Goldman Sachs
New York
|
+$123M |
| 3 |
Citigroup
New York
|
+$119M |
| 4 |
Morgan Stanley
New York
|
+$29.3M |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$29.3M |
